1[1]DJ Wallace. Apheresis for lupus erthematosus. Lupus, (1999)8:174- 180
2[2]Csipo I, Kiss E, soltesz P, et al. Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type Ⅰ (CR Ⅰ )of patient with systemic lupus erythematosus. Clin Exp Immunol, 1999,118(3) :458 - 464
3[3]Jones JV. Response to apheresis:problems of assessment in immune disease. Clin Nephrol, 1986,26 (Suppl 1 ) :70 - 75
4[4]Csipo l,kavai M, kiss E, et al. Serum complememt activation of SLE patients during plasmapheresis. Autoimmunity, 1997, 25 ( 3 ):139 - 146
5[5]Funauchi M, lkoma S, Enomoto H, et al. High affinity anti DNA antibody parallels clinical course of immunoadsorption therapy for systemic lupus erythematosus. Intern Med, 1996,35(5) :367 - 372
6[6]Schiel R, Bambauer R, Lataza R, et al. Cycloporin and plasmapheresis in treatment of progressivae systemic lupus erythematosus.Transfus Sci, 1997, 18( 1 ) :91 - 97
7[7]Sharon Z, Roberts JL, Fennel JS, et al. Plasmapheresis in lupus nephritis. Plasma Ther, 1982,3:165 - 169
8[8]Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trail of plasmapheresis therapy in severe lupus nephritis. N Engl J Med, 1992,326:1373 - 1379
9[9]Wallace DJ. Plasmapheresis for lupus nephritis. N Engl J Med,1992,327:1029
10[10]Gerraty RP, McKelvie PA, Byrne E. Aseptic meningoencephalitis in primary Sj? gren' s syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy. Acta Neurol Scand, 1993,88(4): 309- 11
10Grigor C,Capeli H,Stiding A,et al.Effect of a treatment strategy of fight control for rheumatoid arthritis (The TICORA study):a single-blind randomized controlled trial.Lancet,2004,364:263-269.
